Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) reported strong 2025 results: Group operating income rose to €1,827m (+31% yoy), reported net income to €978m (+82% yoy) and basic EPS to €3.36 (+83% yoy). Operating income margin reached 11.3%, inside the 2025 mid-term target band.

The company recorded €238m of 2025 FME25+ savings (accumulated €804m), announced a €1.0bn buyback (first tranche completed: 14.1m shares for €586m) and proposed a €1.49 dividend (+3%).

Positive

Operating income +31% to €1,827m in FY 2025
Basic EPS +83% to €3.36 in FY 2025
Operating income margin reached 11.3%, within target band
FME25+ delivered €238m incremental savings in 2025
Completed buyback tranche: 14.1m shares for €586m
Proposed dividend €1.49 per share (+3%)

Negative

Divestitures reduced revenue by €244m in 2025 (130 bps headwind)
Corporate operating loss of €119m in FY 2025
FME25+ program costs and planned costs ~€1.2bn through 2027

News Market Reaction – FMS

-7.85%

13 alerts

-7.85% News Effect

-$1.21B Valuation Impact

$14.25B Market Cap

0.4x Rel. Volume

On the day this news was published, FMS declined 7.85%, reflecting a notable negative market reaction. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $1.21B from the company's valuation, bringing the market cap to $14.25B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Organic revenue growth: 8% Operating income growth: 27% Operating margin: 11.3% +5 more

8 metrics

Organic revenue growth 8% Full year 2025 organic revenue growth driven by all segments

Operating income growth 27% Full year 2025 operating income growth, reaching top end of outlook

Operating margin 11.3% Full year 2025 operating income margin within mid-term target band

Net income growth 82% Full year 2025 reported net income increase vs 2024

EPS growth 44% Full year 2025 EPS growth supported by share buyback

Dividend per share EUR 1.49 Planned 2025 dividend proposal, up 3% with 33% payout of adjusted net income

Share buyback program EUR 1.0 billion Total size of ongoing share repurchase program in two tranches

Net financial debt EUR 9.2 billion Net financial debt at end of 2025, 6% lower year-on-year, net leverage 2.5x

Market Reality Check

Price: $22.65 Vol: Volume 586,469 is close t...

normal vol

$22.65 Last Close

Volume Volume 586,469 is close to the 20-day average of 579,196, indicating no major pre-news repositioning. normal

Technical Shares at 24.59 are trading below the 200-day MA of 25.50 and about 19.27% under the 52-week high.

Peers on Argus

Momentum data flagged the stock as moving down, while one peer in momentum rose ...

1 Up 1 Down

Momentum data flagged the stock as moving down, while one peer in momentum rose and one fell, suggesting a stock-specific move rather than a broad Healthcare facilities trade.

Historical Context

5 past events · Latest: Jan 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	HHD growth update	Positive	+1.1%	Reported growth in U.S. home hemodialysis adoption and new VersiHD launch.
Jan 09	Buyback acceleration	Positive	+1.4%	Accelerated second tranche of <b>EUR 1bn</b> share buyback under FME Reignite framework.
Dec 10	Management change	Positive	+3.0%	Appointed new Global Chief Medical Officer to support strategic clinical initiatives.
Nov 04	Q3 2025 earnings	Positive	-7.8%	Reported strong Q3 revenue and operating income growth with margin expansion.
Oct 30	AI & HDF data	Positive	-0.8%	Highlighted real-world HDF outcomes and AI tools at ASN Kidney Week 2025.

Pattern Detected

Most positive announcements have seen supportive price reactions, but strong operational updates have occasionally been followed by negative moves, indicating some history of sell-the-news behavior.

Recent Company History

Over the last few months, the company has focused on innovation, capital returns and profitability. A Q3 2025 update showed higher margins and operating income growth, while a EUR 1.0bn buyback and leadership changes underpinned strategic repositioning. Additional news highlighted home hemodialysis adoption and AI-enabled kidney care. Against this backdrop, the latest full-year 2025 results extend the prior earnings inflection and capital allocation themes with higher margins, EPS growth and balance sheet strengthening.

Market Pulse Summary

The stock moved -7.8% in the session following this news. A negative reaction despite strong 2025 re...

Analysis

The stock moved -7.8% in the session following this news. A negative reaction despite strong 2025 results would fit the history of occasional divergences, such as the Q3 2025 update that coincided with a price decline. The company reported 27% operating income growth, an 11.3% margin and higher EPS, alongside ongoing portfolio optimization and debt reduction. Weakness in this context could reflect profit-taking or skepticism about the flat 2026 revenue outlook rather than the backward-looking earnings strength.

Key Terms

tdapa, hemodiafiltration, high-volume hemodiafiltration, virtual power purchase agreements

4 terms

tdapa regulatory

"higher-than-expected benefits from TDAPA regulation and favorable reimbursement developments"

A transitional drug add-on payment adjustment (TDAPA) is a temporary Medicare payment rule that gives hospitals higher reimbursement for newly available drugs or biologic treatments that are not yet reflected in standard outpatient payment rates. Think of it as a short-term price support that helps hospitals afford and use a new therapy while payers gather real-world cost and effectiveness data—important to investors because it can speed early adoption, stabilize initial revenue for the maker, and reduce commercial risk during the product’s launch.

hemodiafiltration medical

"expand access to high-volume hemodiafiltration in the U.S. with the large-scale rollout"

A blood-cleaning treatment for people whose kidneys fail that combines two actions — one that washes away small dissolved wastes and another that filters out larger particles and excess fluid — using a machine and a sterile replacement fluid. It matters to investors because adoption of this technique affects demand for dialysis machines, disposable supplies, treatment costs and patient outcomes, so shifts in use can change revenues and clinical competitiveness like an equipment upgrade improving both speed and results.

high-volume hemodiafiltration medical

"the high-volume hemodiafiltration (HVHDF) capable 5008X CAREsystem in select U.S. clinics"

High-volume hemodiafiltration is an advanced form of dialysis that cleans a patient’s blood by combining standard dialysis with large-volume fluid exchange to remove more waste and toxins than conventional treatments. For investors it matters because the technique can improve patient outcomes and resource use, which drives demand for specialized machines, consumables and services, influences reimbursement and can shape clinical and regulatory adoption.

virtual power purchase agreements technical

"Humacyte remeasurements... and virtual power purchase agreements amounted to EUR -5 million"

A virtual power purchase agreement is a financial contract where an investor or company agrees to pay a fixed price for electricity produced by a renewable project while the actual power stays on the grid. Think of it like agreeing today on a future price for a crop you won’t physically store — you lock in predictable costs or revenues and trade the difference against market prices. For investors, these deals reduce exposure to volatile energy prices, support renewable development, and can improve the predictability of cash flows and sustainability credentials.

AI-generated analysis. Not financial advice.

02/24/2026 - 07:00 AM

Strong organic revenue growth¹in 2025 of 8% driven by all operating segments
Driven by an exceptional Q4, full year operating income²growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%
Reported operating income grew by 31%, reported net income³ by 82%
Earnings per share² (EPS) grew by 44%, supported by the accelerated share buyback program
Dividend of EUR 1.49 (+3%) planned to be proposed
FY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwinds

BAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025. These achievements reflect our disciplined focus on operational and financial excellence. In 2025, we delivered revenue and operating income growth at the upper end of our outlook, overcoming a difficult market environment," said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Our operating income margin of 11.3% is well within the mid-term margin target band we established three years ago for 2025. The Group's step-up in profitability was the result of solid business growth, accelerated FME25+ efficiency gains, higher-than-expected benefits from TDAPA regulation and favorable reimbursement developments, with all segments making meaningful contributions. This progress underscores our ongoing commitment and value creation focus."

Helen Giza continued, "Looking ahead to 2026, we are set to build on the remarkable transformation of recent years and advance the execution of our FME Reignite strategy. For our patients, we are excited to expand access to high-volume hemodiafiltration in the U.S. with the large-scale rollout of our innovative 5008X CAREsystem. We remain steadfast in our commitment to further improve profitability, while investing in our future and overcoming regulatory headwinds. As such, we expect to grow operating income by three to seven percent CAGR out to 2028 and to increase returns for our shareholders."

Key figures Q4 and FY 2025

	Q4 2025	Q4 2024	Growth	Growth	FY 2025	FY 2024	Growth	Growth
	EUR m	EUR m	yoy	yoy, cc	EUR m	EUR m	yoy	yoy, cc
Revenue	5,070	5,085	0 %	+7 %	19,628	19,336	+2 %	+5 %
Operating income	594	259	+129 %	+144 %	1,827	1,392	+31 %	+36 %
excl. special items²	705	489	+44 %	+53 %	2,212	1,797	+23 %	+27 %
Net income³	327	67	+389 %	+421 %	978	538	+82 %	+88 %
excl. special items²	412	266	+55 %	+64 %	1,248	903	+38 %	+43 %
Basic EPS (EUR)	1.14	0.23	+402 %	+434 %	3.36	1.83	+83 %	+89 %
excl. special items²	1.44	0.91	+59 %	+68 %	4.28	3.08	+39 %	+44 %

yoy = year-on-year, cc = at constant currency, EPS = earnings per share

FME Reignite set for next phase of value creation
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, successfully concluded its milestone year 2025 and embarked into the next phase of value creation with its FME Reignite strategy. Introduced at the Capital Markets Day in June 2025, the new strategy focuses on strengthening our core operations, driving profitable growth and innovation, and advancing the company culture.

In 2025, Fresenius Medical Care began a soft launch of the high-volume hemodiafiltration (HVHDF) capable 5008X CAREsystem in select U.S. clinics, with plans for a large-scale rollout starting in 2026. The company invests in the training of over 7,200 nurses and technicians and the transition of about 36,000 patients to the new system across 28 states. By replacing approximately 20% of its dialysis machines every year, Fresenius Medical Care aims to provide faster access to this therapy and its associated mortality benefits.

Operational efficiency: In 2025, the FME25+ transformation program further accelerated its positive momentum, delivering EUR 238 million additional sustainable savings for the full year 2025, ahead of the upgraded full year target of around EUR 220 million. Accumulated savings of the entire program reached EUR 804 million. Related one-time costs, treated as special items, were EUR 194 million in 2025, adding up to EUR 793 million since the start of the program in 2021. The company is continuing its strong progress and will accelerate and further expand the FME25+ program. It now projects additional savings of EUR 150 million, increasing the total to EUR 1.2 billion by the end of 2027. Program costs are expected to also be around EUR 1.2 billion within the same period.

Portfolio Optimization: Fresenius Medical Care continued the execution of its portfolio optimization plan to exit non-core and dilutive assets, emphasizing the company´s focus on product areas, businesses and markets with the best strategic fit, scale and sustainable profitable growth potential. Transactions negatively impacted revenue by EUR 244 million in 2025, translating into a 130 basis points growth headwind. The related negative impact on operating income was EUR 97 million in the full year 2025, treated as special item. All assets divested since 2023 include 391 facilities, around 12,600 employees and 53,600 dialysis patients.

Dividend and share buyback: In 2025, Fresenius Medical Care introduced a new capital allocation framework. The framework foresees a stable and predictable dividend development that results in a payout ratio of 30% to 40% of net income⁴. The planned dividend proposal for fiscal year 2025 of EUR 1.49 per share is a 3% increase and corresponds to a payout of 33% of adjusted net income. Shareholder returns through dividends are complemented by a share buyback program of EUR 1.0 billion currently being executed in two tranches. The first tranche of up to EUR 600 million was initiated on August 11, 2025, and completed in an accelerated way on December 29, 2025. As of December 31, 2025, 14.1 million shares were repurchased for a total investment amount of EUR 586 million. The second tranche of around EUR 414 million started on January 12, 2026, and is planned to end by May 8, 2026. The entire program is therefore expected to be completed in less than one year instead of within two years.

In parallel, net financial debt was further reduced by 6% to EUR 9.2 billion. The corresponding net leverage ratio (net debt/EBITDA) decreased to 2.5x at the end of 2025, compared to 2.9x at the end of 2024, and sits at the lower end of the target corridor of 2.5x to 3.0x.

Fresenius Medical Care ends the year with strong revenue growth
In the fourth quarter 2025, Group revenue remained stable compared to prior year (+7% at constant currency, +8% organic¹) with EUR 5,070 million. Strong organic revenue growth was driven by Value-Based Care and Care Delivery. Significant currency effects negatively impacted revenue development in all three operating segments. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development by 70 basis points.

Care Delivery revenue decreased by 2% (+6% at constant currency, +7% organic¹) to EUR 3,507 million. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development by 120 basis points.

In Care Delivery U.S., revenue decreased by 1% (+8% at constant currency, +8% organic¹) to EUR 2,956 million. Impacts from TDAPA reimbursement regulations, favorable rate and payor mix effects, and reduced implicit price concessions had a positive impact while exchange rates developed unfavorably. U.S. same market treatment growth remained flat (-0.2%).

In Care Delivery International, revenue decreased by 6% (-4% at constant currency, +3% organic¹) to EUR 551 million. The effects of closed or sold operations, mainly related to portfolio optimization, and unfavorable exchange rates were partially offset by organic growth¹. International same market treatment growth amounted to 1.7%.

Value-Based Care revenue significantly grew by 32% (+42% at constant currency, +42% organic¹) to EUR 637 million. Growth in the quarter was driven by a significantly higher number of member months mainly due to contract expansion, while exchange rates developed unfavorably.

Care Enablement revenue decreased by 9% (-3% at constant currency, -3% organic¹) to EUR 1,401 million. Unfavorable exchange rate effects as well as lower volumes, driven by negative impacts from volume-based procurement and other regulatory policies in China, were partly offset by overall positive pricing momentum.

Within Inter-segment eliminations⁵, revenue for services provided and products transferred between the operating segments at fair market value came in at negative EUR 475 million.

In the full year 2025, Group revenue increased by 2% (+5% at constant currency, +8% organic¹) to EUR 19,628 million. Divestitures realized as part of the portfolio optimization plan negatively impacted the revenue development by 130 basis points. Care Delivery revenue decreased by 2% (+2% at constant currency, +5% organic¹) to EUR 13,736 million, with Care Delivery U.S. flat year-on-year (+4% at constant currency, +5% organic¹) at EUR 11,507 million and Care Delivery International decreasing by 10% (-9% at constant currency, +4% organic¹) to EUR 2,229 million. Divestitures realized as part of the portfolio optimization plan negatively affected the revenue development of Care Delivery by 210 basis points and the revenue development of Care Delivery International by 1,200 basis points. U.S. same market treatment growth came in flat (0.0%) while international same market treatment growth amounted to 2.0%. Value-Based Care revenue increased by 28% (+34% at constant currency, +34% organic¹) to EUR 2,247 million. Care Enablement revenue decreased by 1% (+2% at constant currency, +2% organic¹) to EUR 5,476 million. Inter-segment eliminations decreased to a deduction of EUR 1,831 million.

Strong earnings growth momentum and double-digit operating income margin
In the fourth quarter 2025, Group operating income more than doubled and increased by 129% (+144% at constant currency) to EUR 594 million, resulting in a margin of 11.7% (Q4 2024: 5.1%). Operating income excluding special items significantly increased by 44% (+53% at constant currency) to EUR 705 million, resulting in a margin² of 13.9% (Q4 2024: 9.6%). Divestitures realized during the fourth quarter were neutral on operating income margin development.

Operating income in Care Delivery increased by 103% (+122% at constant currency) to EUR 528 million, resulting in a margin of 15.1% (Q4 2024: 7.3%). Operating income excluding special items significantly grew by 34% (+45% at constant currency) to EUR 574 million, resulting in a margin² of 16.4% (Q4 2024: 12.0%). Compared to previous year, operating income development was driven by the further accelerated positive impact from TDAPA reimbursement regulations, positive rate and payor mix effects, income attributable to a consent agreement on certain pharmaceuticals and savings from the FME25+ program. The development was negatively impacted by higher personnel expenses including elevated medical benefit costs as well as other inflationary cost increases.

Operating income in Value-Based Care increased to EUR 29 million, compared to a loss of EUR 7 million in the prior year, resulting in a margin of 4.5% (Q4 2024: -1.4%) and reflecting the quarterly earnings volatility, which is inherent to the business model. There were no special items in the fourth quarter of the current and prior year. The improvement compared to the previous year's quarter was driven by a favorable savings rate for certain contracts, partially offset by an unfavorable effect from CKCC programs.

Operating income in Care Enablement decreased by 21% (-20% at constant currency) to EUR 56 million, resulting in a margin of 4.0% (Q4 2024: 4.6%). Operating income excluding special items decreased by 9% (-6% at constant currency) to EUR 107 million, resulting in a margin² of 7.7% (Q4 2024: 7.7%). The development compared to the previous year's quarter was mainly driven by lower volumes in China, inflationary cost increases which developed in line with expectations, as well as higher-than-expected currency transaction effects. These negative effects were partially offset by savings from the FME25+ program and overall positive pricing developments.

Operating income for Corporate amounted to a loss of EUR 41 million (Q4 2024: loss of EUR 57 million). Humacyte remeasurements, treated as a special item in the Corporate line, amounted to EUR -14 million and virtual power purchase agreements amounted to EUR -5 million. Operating income excluding special items amounted to a loss of EUR 27 million (Q4 2024: loss of EUR 44 million).

In the full year 2025, Group operating income increased by 31% (+36% at constant currency) to EUR 1,827 million, resulting in a margin of 9.3% (FY 2024: 7.2%). Operating income excluding special items increased by 23% (+27% at constant currency) to EUR 2,212 million, reaching the upper end of the full year outlook and resulting in a margin² of 11.3% (FY 2024: 9.3%) within the 2025 mid-term target band. Divestitures realized during the full year were neutral on operating income margin² development. In Care Delivery, operating income increased by 33% (+40% at constant currency) to EUR 1,614 million, resulting in a margin of 11.8% (FY 2024: 8.7%). Operating income excluding special items increased by 13% (+19% at constant currency) to EUR 1,801 million, resulting in a margin² of 13.1% (FY 2024: 11.4%), within the 2025 mid-term target band. In Value-Based Care operating income improved to EUR 1 million compared to a loss of EUR 28 million in the prior year, resulting in a margin of 0.1% (FY 2024: -1.6%). Operating income excluding special items improved to EUR 3 million compared to a loss of EUR 28 million in the prior year, in line with the full year target of turning break-even and resulting in a positive margin²of 0.1% (FY 2024: -1.6%). In Care Enablement, operating income increased by 22% (+23% at constant currency) to EUR 326 million, resulting in a margin of 6.0% (FY 2024: 4.8%). Operating income excluding special items increased by 32% (+33% at constant currency) to EUR 442 million, resulting in a margin² of 8.1% (FY 2024: 6.0%), within the 2025 mid-term target band. Operating income for Corporate amounted to a loss of EUR 119 million (FY 2024: loss of EUR 48 million). Operating income excluding special items improved to a loss of EUR 38 million (FY 2024: loss of EUR 80 million), mainly due to a favorable impact from the valuation of virtual power purchase agreements.

Net income³ more than quadrupled compared to prior year (+421% at constant currency) to EUR 327 million in the fourth quarter 2025. Net income excluding special items increased by 55% (+64% at constant currency) to EUR 412 million.

In the full year 2025, net income³significantly increased by 82% (+88% at constant currency) to EUR 978 million. Net income excluding special items increased by 38% (+43% at constant currency) to EUR 1,248 million.

Basic earnings per share (EPS) more than quadrupled compared to prior year (+434% at constant currency) to EUR 1.14 in the fourth quarter 2025, based on 285,906,303 shares. Basic EPS excluding special items increased by 59% (+68% at constant currency) to EUR 1.44.

In the full year 2025, basic EPS increased by 83% (+89% at constant currency) to EUR 3.36, based on 291,190,575 shares. Basic EPS excluding special items increased by 39% (+44% at constant currency) to EUR 4.28.

Solid cash flow growth, net leverage ratio at low end of target corridor
In the fourth quarter 2025, operating cash flow increased by 20% to EUR 1,002 million (Q4 2024: EUR 832 million), resulting in a margin of 19.8% (Q4 2024: 16.4%). In the full year 2025, operating cash flow improved by 12% to EUR 2,681 million (FY 2024: EUR 2,386 million). The related margin came in at 13.7% (FY 2024: 12.3%). Both developments were mainly driven by the increase in net income, the improvement in cash collections and prior-year phasing of income tax payments.

During the quarter, the company closed the agreement to purchase its main production sites in Schweinfurt and St. Wendel, Germany, from Fresenius SE for a total amount of EUR 181 million.

Free cash flow⁶decreased by 2% to EUR 584 million in the fourth quarter 2025 (Q4 2024: EUR 599 million), resulting in a margin of 11.5% (Q4 2024: 11.8%). In the full year 2025, Fresenius Medical Care increased free cash flow by 5% to EUR 1,782 million (FY 2024: EUR 1,701 million), resulting in a margin of 9.1% (FY 2024: 8.8%).

Total net debt and lease liabilities were further reduced to EUR 9,196 million (Q4 2024: EUR 9,803 million). The net leverage ratio (net debt/EBITDA) further improved to 2.5x in Q4 2025 (Q3 2025: 2.6x), thus finishing the year at the lower end of our 2.5x to 3.0x target band.

Patients, clinics and employees
As of December 31, 2025, Fresenius Medical Care treated 291,902 patients in 3,601 dialysis clinics worldwide and had 109,698 employees (headcount) globally.

Outlook 2026
In 2026, Fresenius Medical Care expects revenue growth to be broadly flat compared to prior year. The company expects operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year.

The expected growth rates for 2026 are at constant currency and excluding special items in operating income. The 2025 basis for the revenue outlook is EUR 19,628 million and for the operating income outlook is EUR 2,212 million.

Aspirations 2028 and 2030
Fresenius Medical Care aspires operating income growth (CAGR) of between 3 and 7 percent between 2025 and 2028.

Fresenius Medical Care aspires revenue growth (CAGR) between 2025 and 2030 for Care Delivery to amount to a low- to mid-single digit percent rate and for Care Enablement to a mid-single digit percent rate.

The company confirms its 2030 aspiration to achieve an industry-leading mid-teens percent operating income margin for the Group, for Care Delivery and for Care Enablement as well as a low single-digit operating income margin for Value-Based Care.

The assumed growth rates are at constant currency and exclude special items. The assumed margins exclude special items in operating income.

Press conference
Fresenius Medical Care will host a virtual press conference to discuss the results of the fourth quarter and the full year 2025 today, February 24, 2026, at 10:00 a.m. CET / 4:00 a.m. EST.

Investor conference call
Fresenius Medical Care will host a conference call for analysts and investors to discuss the results of the fourth quarter and full year 2025 today, February 24, 2026, at 2:00 p.m. CET / 8:00 a.m. EST. Details are available on the Fresenius Medical Care website in the "Investors" section. A replay and a transcript will be available shortly after the call.

Please refer to our statement of earnings included at the end of this press release and to the attachments as separate PDF files for a complete overview of the results of the fourth quarter and full year 2025. Our form 20-F disclosure provides more details.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,601 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 292,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

____________________
¹	At constant currency, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days
²	Adjusted for special items; growth rate at constant currency (if not stated otherwise); for further details please see the reconciliation attached to the press release
³	Net income attributable to shareholders of Fresenius Medical Care AG
⁴	Net income attributable to shareholders of FME AG excluding special items
⁵	The company transfers products from the Care Enablement segment to the Care Delivery segment at fair market value. Services provided by the Care Delivery segment for patients managed under the Value-Based Care segment are also provided at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within "Inter-segment eliminations".
⁶	Net cash provided by / used in operating activities, after capital expenditures, before acquisitions, investments, and dividends

Statement of earnings
	Three months ended December 31,
in € million, except share data	2025	2024	Change	Change at cc

Revenue	5,070	5,085	-0.3 %	7.1 %

Costs of revenue	3,681	3,814	-3.5 %	3.9 %
Selling, general and administrative expense	785	840	-6.5 %	-0.6 %
Research and development expense	39	50	-22.8 %	-20.6 %
Income from equity method investees	(42)	(32)	29.7 %	29.9 %
Other operating income	(131)	(228)	-42.5 %	-40.8 %
Other operating expense	144	382	-62.3 %	-60.5 %
Operating income	594	259	129.4 %	143.6 %
Operating income excl. special items¹	705	489	44.2 %	52.9 %

Interest expense, net	85	80	7.0 %	14.1 %
Income before taxes	509	179	183.9 %	201.2 %
Income tax expense	106	61	74.5 %	81.9 %
Net income	403	118	240.4 %	262.8 %
Net income attributable to noncontrolling interests	76	51	46.3 %	56.6 %
Net income²	327	67	388.9 %	420.8 %
Net income² excl. special items¹	412	266	54.9 %	63.9 %

Weighted average number of shares	285,906,303	293,413,449

Basic earnings per share	€1.14	€0.23	401.8 %	434.4 %
Basic earnings per share excl. special items¹	€1.44	€0.91	59.0 %	68.2 %

In percent of revenue
Operating income margin	11.7 %	5.1 %
Operating income margin excl. special items¹	13.9 %	9.6 %


¹ For a reconciliation of special items, please refer to the table at the end of the press release.
² Attributable to shareholders of FME AG.

Statement of earnings
	Twelve months ended December 31,
in € million, except share data	2025	2024	Change	Change at cc

Revenue	19,628	19,336	1.5 %	5.4 %

Costs of revenue	14,599	14,579	0.1 %	4.1 %
Selling, general and administrative expense	3,033	3,143	-3.5 %	-0.2 %
Research and development expense	158	183	-13.9 %	-12.6 %
Income from equity method investees	(181)	(135)	34.5 %	34.5 %
Other operating income	(528)	(760)	-30.5 %	-29.4 %
Other operating expense	720	934	-22.8 %	-21.0 %
Operating income	1,827	1,392	31.2 %	35.6 %
Operating income excl. special items¹	2,212	1,797	23.1 %	27.2 %

Interest expense, net	315	335	-6.2 %	-3.1 %
Income before taxes	1,512	1,057	43.1 %	47.9 %
Income tax expense	321	316	1.6 %	4.4 %
Net income	1,191	741	60.8 %	66.5 %
Net income attributable to noncontrolling interests	213	203	4.9 %	9.4 %
Net income²	978	538	81.9 %	88.0 %
Net income² excl. special items¹	1,248	903	38.2 %	42.6 %

Weighted average number of shares	291,190,575	293,413,449

Basic earnings per share	€3.36	€1.83	83.3 %	89.4 %
Basic earnings per share excl. special items¹	€4.28	€3.08	39.3 %	43.7 %

In percent of revenue
Operating income margin	9.3 %	7.2 %
Operating income margin excl. special items¹	11.3 %	9.3 %


¹ For a reconciliation of special items, please refer to the table at the end of the press release.
² Attributable to shareholders of FME AG.

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company´s outlook
	Three months ended December 31,		Twelve months ended December 31,
in € million	2025	2024	2025	2024

Operating performance excl. special items
These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items.

Revenue	5,070	5,085	19,628	19,336

Operating income	594	259	1,827	1,392
FME25+ Program¹	73	73	194	180
Legacy Portfolio Optimization²	18	146	97	288
Legal Form Conversion Costs	2	4	4	9
Humacyte Remeasurements	18	7	90	(72)
Sum of special items:	111	230	385	405
Operating income excl. special items	705	489	2,212	1,797

Net income³	327	67	978	538
FME25+ Program¹	54	53	143	130
Legacy Portfolio Optimization²	16	138	91	282
Legal Form Conversion Costs	1	3	3	7
Humacyte Remeasurements	14	5	67	(54)
Interwell Health Deferred Tax Reversal⁴	0	—	(34)	—
Sum of special items:	85	199	270	365
Net income³ excl. special items	412	266	1,248	903


¹The FME25 Program was expanded by two years, the overall savings target increased and renamed to the FME25+ Program.
² 2025: mainly related to the completed divestitures in Brazil, Malaysia, and Kazakhstan as well as the select assets of FME AG's wholly owned Spectra Laboratories, and impairment losses primarily related to right-of-use assets; 2024: mainly comprise gains and losses from divestitures, impairment losses resulting from the measurement of assets held for sale or from write-downs of related non-current assets.
³ Attributable to shareholders of FME AG.
⁴ Derecognition of certain deferred tax liabilities initially established in connection with the 2022 Interwell Health Transaction as a result of the settlement of Interwell Health put options.

Media contact
Christine Peters
T +49 160 60 66 770
Christine.Peters@FreseniusMedicalCare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
Dominik.Heger@FreseniusMedicalCare.com

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-delivers-27-earnings-growth-in-2025-and-reaches-upper-end-of-its-financial-outlook-margin-within-2025-mid-term-target-band-302695592.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What were Fresenius Medical Care (FMS) full-year operating income and margin for 2025?

Full-year operating income was €1,827m with an operating margin of 11.3%. According to the company, operating income rose 31% year-on-year and the 11.3% margin sits within the 2025 mid-term target band, reflecting improved profitability and efficiency gains.

How did Fresenius Medical Care (FMS) EPS change in 2025 and what supported the increase?

Basic EPS rose to €3.36, an increase of 83% year-on-year. According to the company, the EPS gain was supported by higher earnings and an accelerated share buyback (first tranche repurchased 14.1 million shares for €586m).

What savings did the FME25+ program deliver for Fresenius Medical Care (FMS) in 2025?

FME25+ delivered €238m of additional sustainable savings in 2025. According to the company, accumulated program savings reached €804m and total expected savings will increase to €1.2bn by end of 2027, with related program costs also planned around €1.2bn.

How large is Fresenius Medical Care's (FMS) share buyback and what progress has been made?

The company launched a €1.0bn buyback program, executing it in two tranches. According to the company, the first tranche completed on December 29, 2025 repurchasing 14.1 million shares for €586m; the second tranche began January 12, 2026.

What revenue impact did portfolio optimization/divestitures have on Fresenius Medical Care (FMS) in 2025?

Divestitures reduced revenue by €244m in 2025, equivalent to a 130 basis points growth headwind. According to the company, assets divested since 2023 included 391 facilities, about 12,600 employees and 53,600 dialysis patients.

What is Fresenius Medical Care's (FMS) outlook for operating income and leverage going into 2026?

The company expects operating income to remain on a consistent level in 2026 despite headwinds. According to the company, net financial debt fell to €9.2bn and net leverage reduced to 2.5x, at the lower end of its 2.5x–3.0x target corridor.

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band